TD Cowen raises Charles River Labs stock price target on growth outlook
TD Cowen raised its price target for Charles River Laboratories (NYSE:CRL) to $325 from $300, citing 5-7% organic revenue growth and low double-digit EPS growth through 2030. The stock is near its 52-week high after a 102% gain over the past year. Analysts forecast $11.63 EPS for fiscal 2026, with the Discovery and Safety Assessment segment seen as a key growth driver. CRL recently reported Q2 2026 earnings and revenue above expectations, raising its full-year outlook.
How this was made
The 30-second read
Why it matters
Analyst upgrades provide a modest bullish signal but no new fundamental data.
Market read
The coverage highlights modest upside for CRL but adds little new information beyond already‑released earnings.
What to watch
Potential headwinds from refinancing costs and margin pressure in 2027.
Background
The article recaps Charles River Labs' Q2 2026 earnings and subsequent analyst price‑target upgrades.
Ticker impact
TD Cowen raises price target to $325 and maintains Buy rating on Charles River Labs.
Modest upside if investors follow the new target.
Target raise reflects growth outlook but follows already‑released earnings; limited new catalyst.
Market effects
Reinforces positive sentiment for the preclinical services sector.
Limited to US biotech/health‑services investors.
Minimal global effect.
Counterpoint
Target raise may be premature given modest organic growth expectations.
Key entities
- AnalystTD Cowen
Raised price target to $325.
- AnalystJPMorgan
Upgraded to Overweight and raised target to $310.
